Changes in serum sclerostin in post-menopausal women with osteoporosis treated with recombinant human parathyroid hormone (1-34)
10.3760/cma.j.issn.1000-6699.2013.07.009
- VernacularTitle:重组人甲状旁腺素(1-34)治疗绝经后骨质疏松症妇女血清骨硬化蛋白水平的变化
- Author:
Jing CAI
;
Tingting ZHOU
;
Changhui GUO
;
Shushan DU
- Publication Type:Journal Article
- Keywords:
Recombinant human parathyroid hormone (1-34);
Sclerostin;
Osteoporosis;
Postmenopausal
- From:
Chinese Journal of Endocrinology and Metabolism
2013;29(7):575-578
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate changes in serum sclerostin (SO) in postmenopausal women before and after treatment with recombinant human parathyroid hormone (1-34) [rhPTH (1-34)],and to explore the relationship of serum SO with estradiol (E2),and bone mineral density (BMD).Methods Ninety-five postmenopausal women were divided into normal BMD group (n =41) and osteoporosis group (n =54).Body mass index,alkaline phosphatase (ALP),serum E2,calcium,phosphate,and SO were determined in both groups.The patients in osteoporosis group were treated with rhPTH (1-34) 20 μg/d by subcutaneous injection and oral calcium 500 mg/d for 12 months.Serum calcium,serum phosphate,BMD,serum ALP,serum E2,and sclerostin were determined in osteoporosis group by 6 months and 12 months of treatment.Results (1) Serum level of SO in osteoporosis group was raised significantly as compared with normal BMD group (P ＜ 0.05) ; E2 and BMD were negatively correlated with SO; age and postmenopausal years were positively correlated with SO (P ＜ 0.05).(2) Serum SO was reduced gradually with treatment of rhPTH (1-34) by 6 months and 12 months (P ＜ 0.05).Conclusions Serum SO was increased in postmenopausal women,which was related to E2 and BMD,and was reduced gradually with treatment of rhPTH (1-34).SO may participate in the development of postmenopausal osteoporosis.
